Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX)
Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a report issued on Friday morning,Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the stock. IMRX has been the topic of a number of other reports. Chardan Capital restated a “buy” rating and […]
Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a report issued on Friday morning,Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the stock. IMRX has been the topic of a number of other reports. Chardan Capital restated a “buy” rating and […]
